Compare AKAN & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKAN | NXTS |
|---|---|---|
| Founded | 2021 | 2009 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 2.4M |
| IPO Year | 2021 | 2021 |
| Metric | AKAN | NXTS |
|---|---|---|
| Price | $2.79 | $1.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 520.3K | 16.2K |
| Earning Date | 05-12-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $263,445.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.42 | $0.55 |
| 52 Week High | $78.90 | $23.80 |
| Indicator | AKAN | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 30.80 | 35.76 |
| Support Level | $0.67 | $1.43 |
| Resistance Level | $3.40 | $2.08 |
| Average True Range (ATR) | 0.46 | 0.13 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 1.58 | 9.00 |
Akanda Corp is a cannabis cultivation, manufacturing, and distribution company. The company is a medical cannabis & hemp and wellness platform company seeking to help people lives through improved access to high-quality and affordable products. The Company is also in the business of leasing fiber optic networks and telecommunication towers, through its subsidiary. The company has four reportable segments: Infrastructure, Cultivation, Distribution, and Corporate. A majority of its revenue is generated from the Infrastructure segment, which relates to the leasing and/or rental of fiber optic networks and telecommunication towers at First Towers in Mexico.
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.